Related Experiment Video
Updated: Sep 9, 2025
A Real-time Potency Assay for Chimeric Antigen Receptor T Cells Targeting Solid and Hematological Cancer Cells
Published on: November 12, 2019
CD70 as a target in cancer immunotherapy: advances, challenges, and future directions
Ruchen Wu1, Junze Chen1, Gang Wang1,2,3
1Cancer Institute, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Cancer immunotherapy represents a paradigm shift in oncology by leveraging the immune system to target tumors. The therapeutic efficacy of these approaches depends critically on identifying molecular targets that enhance treatment responses while limiting toxicity. CD70, a TNF family member, has emerged as a promising target due to its overexpression in hematologic malignancies and solid tumors contrasted with restricted expression in healthy tissues. This differential expression profile implies that CD70-directed therapies could achieve tumor-specific cytotoxicity with reduced off-target effects. Nevertheless, key challenges persist, including optimizing delivery systems and elucidating the immunological consequences of CD70 modulation. This review synthesizes recent progress in CD70-targeted immunotherapy, evaluating both its therapeutic potential and current constraints to guide future clinical translation.
Cancer immunotherapy represents a paradigm shift in oncology by leveraging the immune system to target tumors. The therapeutic efficacy of these approaches depends critically on identifying molecular targets that enhance treatment responses while limiting toxicity. CD70, a TNF family member, has emerged as a promising target due to its overexpression in hematologic malignancies and solid tumors contrasted with restricted expression in healthy tissues. This differential expression profile implies that CD70-directed therapies could achieve tumor-specific cytotoxicity with reduced off-target effects. Nevertheless, key challenges persist, including optimizing delivery systems and elucidating the immunological consequences of CD70 modulation. This review synthesizes recent progress in CD70-targeted immunotherapy, evaluating both its therapeutic potential and current constraints to guide future clinical translation.
Frequently Asked Questions
CD70-targeted immunotherapy leverages the differential expression of this ligand, which is overexpressed in tumors but restricted in healthy tissues, to achieve tumor-specific cytotoxicity while minimizing off-target effects.
As a member of the Tumor Necrosis Factor (TNF) superfamily, CD70 exhibits a differential expression profile that is significantly higher in malignant cells than in healthy tissues, allowing for precise tumor-specific cytotoxicity.
The systematic synthesis revealed that CD70 overexpression occurs in both hematologic malignancies and solid tumors, providing a broad evidence base for the development of targeted immunological interventions across multiple oncological categories.
The study identifies that optimizing delivery systems and understanding the immunological consequences of modulating this ligand remain primary challenges that must be resolved before widespread clinical translation.
The authors state that future efforts should focus on evaluating the therapeutic potential and current constraints of these agents to guide the development of more effective tumor-specific cytotoxicity protocols.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers